

## **Sajeve Samuel Thomas**

### **Present Mailing Address**

1814 Lake Roberts Ct  
Windermere FL 34786  
Preferred Phone: 9546637551  
Alternate Phone: 9546639740  
[sajeve.thomas@orlandohealth.com](mailto:sajeve.thomas@orlandohealth.com)  
[sajimone@gmail.com](mailto:sajimone@gmail.com)

### **Medical Oncologist –Cutaneous/Sarcomas/Gastrointestinal Malignancies**

Director of Cutaneous/Sarcoma Section  
Orlando Health Cancer Institute at Orlando Health  
8/2011 – Present

### **Clinical Investigator – Cutaneous/Sarcomas/Gastrointestinal Malignancies**

Orlando Health Cancer Institute at Orlando Health  
Phase I/II/III clinical trials  
2014 - Present

### **Clinical Investigator – Melanoma/GI Section**

MD Anderson Cancer Center Orlando  
8/2011 – 2014

### **Medical Oncology/Hematology Expert Witness**

2013 – Present

### **Foundation One Genomic Tumor Board (National and International)**

Medical Oncology consultant  
2018-2021

### **Medical Oncology Consultant**

BMS, Merck, Ipsen, Novartis, Array, Amgen, Genentech  
2013 – Present

### **UCF College of Medicine Assistant Professor**

University of Central Florida, Orlando  
10/2011 – Present

### **FSU College of Medicine Assistant Professor**

University of Central Florida, Orlando  
10/2011 – Present

### **Chief Fellow - Hematology/Oncology**

University of Florida, Gainesville, Florida  
7/2010 – 6/2011

### **Board Review Coordinator Hematology-Oncology**

University of Florida, Gainesville, Florida  
7/2009– 6/2011

### **Hematology/Oncology Fellowship**

University of Florida, Gainesville, Florida  
7/2008 – 6/2011

### **Internal Medicine Residency**

University of South Florida IM, Tampa, Florida  
7/2005 – 6/2008

**Medical Education**

University of Florida College of Medicine, Gainesville, Florida  
Medical Doctorate  
7/2001 - 6/2005

**Undergraduate**

University of South Florida, Tampa, FL  
B.A. Computer Science  
8/1997 - 6/2001

**Dual Enrollment**

Broward Community College, Davie, FL  
1/1997 - 5/1997

**School Awards & Membership in Honorary/Professional Societies**

NANET - member  
NSABP - member  
American Society of Hematology - Member  
American Society of Clinical Oncology - Member  
American College of Physicians  
Outstanding Resident Award USF  
Residents and Fellows of Indian Origin, Tampa Bay Chapter  
Golden Key National Honor Society

**Certification/Licensure**

Diagnosis and Management of Coagulation Disorders 12/04/08  
Fully licensed in state of Florida 7/08  
ACLS Certified 7/07

**Examinations**

Hematology and Oncology Board Certified 11/2012  
Hematology In-Service Exam 2/2010 - **90<sup>th</sup> Percentile**  
Oncology In-Service Exam 3/2010 - **90<sup>th</sup> Percentile**  
American Board of Internal Medicine 8/08 - Passed / Board Certified  
USMLE Step 3 8/2007  
USMLE Step 2 CS (Clinical Skills) 1/2005  
USMLE Step 2 CK (Clinical Knowledge) 11/2004  
USMLE Step 1 6/2003

**Awards/Accomplishments**

Patient KIOSK Improved Perception Waiting- 2014  
Clinical scribe - piloted first with improved clinic efficiency, notes, staging, orders  
Narrative templates - improved pt oncology summary, billing, coding, presentation  
ASCO Conquer Cancer Mentor Award 6-7/2012  
Pfizer Drug Development Simulation - Program Manager for the Winning Team  
Hem/Onc Pharmacology Jeopardy - 1<sup>st</sup> Place  
Outstanding Resident Award - Distinction given to only 10% of our class  
Dean's List Four Consecutive Years  
Engineering Dean's List  
USF Scholar Award by USF Honor's Program  
Golden Key National Honor Society Scholar

**Publications**

Lifileucel, a Tumor-infiltrating Lymphocyte Therapy, in Metastatic Melanoma.

- 2020 In submission

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab ovitecan, for the Treatment of Diverse Metastatic Solid Tumor.

- Clin Cancer Res 2015 Sep 1;21(17):3870-8 PMID: 25944802

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.

- Clin Cancer Res 2020 May. PMID: 31980466

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.

- J Immunother Cancer 2016 Aug PMID: 27532019

Melanoma/Sarcoma Rotational Curriculum for MDACCO Fellowship Program

"Institutional Review In The Treatment of Bladder/Upper Urinary Tract Malignancies"

*Retrospective review*

"Updated Review In the Management of Patients With Metastatic Brain Disease" Published in *Current Oncology*

Case Report: "Unique Polymorphism of Low Cytochrome b5 Expression in a Patient With Methemoglobinemia" submitted to the Journal of Clinical Pharmacology

### **Volunteer Experience**

3/2012 – Metro Church Health Fair – Panelist

7/2009 – 6/2010 Hematology/Oncology Board Review Coordinator

7/2008 – 6/2010 Medical Student Preceptor for Hematology/Oncology Education

8/2001 - 5/2005 Equal Access Clinic – Indigent Care Clinic

8/1999 - 5/2001 Golden Key National Honor Society Webmaster

8/1998 - 5/1999 Minority Pre-Professional Science Society – Vice President

1/1996 - 5/1997 IPC Church of God - Youth Coordinator and Pianist

### **Research**

*Principal Investigator*

A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

*Principal Investigator*

OMS-I103-- The Pisces Study: A Multicenter phase 2, open-label trial of Intratumoral Tavokinogene Telseplasmid (tavo, PIL-12) plus Electroporation in combination with intravenous Pembrolizumab in patients with stage III/IV Melanoma who are progressing on either Pembrolizumab or Nivolumab treatment

*Principal Investigator*

C-144-01- A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma

*Principal Investigator*

IOV-COM-202- A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors

*Principal Investigator*

CA209-238 - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence (CheckMate 238: CHECKpoint pathway and nivolumab clinical Trial Evaluation 238)

*Principal Investigator*

CA209915- A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915: CHECKpoint pathway and nivolumab clinical Trial Evaluation 915)

*Principal Investigator*

CL-CA-P01-Phase III, Randomized, Double-Blind, Multicenter Trial Of Autologous Dendritic Cells Loaded With Irradiated Autologous Tumor Cells (NBS20) Vs. Autologous Peripheral Blood Mononuclear Cell Control (MC), Both Coadministered With Adjuvant GM-CSF, For The Treatment Of Patients With Metastatic Melanoma

*Principal Investigator*

CA017-055- A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined with Nivolumab versus Nivolumab in Participants with Metastatic or Unresectable Melanoma that is Previously Untreated

*Principal Investigator*

2125-MEL-301- A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

*Principal Investigator*

CA209-037 - A Randomized, Open-Label Phase III Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy.

*Principal Investigator*

CA209218 - Expanded Access Program with Nivolumab (BMS-936558) in Combination with Ipilimumab (Yervoy) in Subjects with Unresectable or Metastatic Melanoma

*Principal Investigator*

CA209-238 - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence (CheckMate 238: CHECKpoint pathway and nivolumab clinical Trial Evaluation 238)

*Principal Investigator*

103A-301- A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (MAVIS= Melanoma Antigen Vaccine Immunotherapy Study).

*Principal Investigator*

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing Of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma

*Principal Investigator*

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

*Principal Investigator*

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

*Principal Investigator*

LX1606-303: A Phase 3, Randomized, Placebo-controlled, Multicenter, Doubleblind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome

*Principal Investigator*

NSABP MPR-1 - NSABP Patient Registry and Biospecimen Profiling Repository

*Principal Investigator*

STX0112 - Assessment of Overall Survival of FOLFOX6m plus SIR-Spheres,¥ microspheres versus FOLFOX6m alone as first-line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma in a randomised clinical study

*Principal Investigator*

BT-CL-PGG-CRC1031 - A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbix®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer

*Principal Investigator*

IMMU-130-02- A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14- SN38,

Antibody-Drug Conjugate) in Patients with Colorectal Cancer

*Principal Investigator*

GS-US-295-0203: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma that Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen

*Principal Investigator*

IMMU-132-01 - A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer

*Principal Investigator*

NSABP FC-7 - A Phase I/II Dose-Escalation Study Evaluating the Combination of Neratinib and Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Resistant to Cetuximab

*Sub Investigator*

PACE Clinical trial RCT using Bone Marrow Stem Cells in Patients with Severe PVD Bone marrow Harvest

*Sub Investigator*

050012: A Phase I/II Clinical Trial Evaluating DCVax-Direct, Autologous Activated Dendritic Cells for Intratumoral Injection, in Patients with Solid Tumors

*Sub Investigator*

CA184-338 - A MULTI-SITE RETROSPECTIVE OBSERVATIONAL STUDY OF US PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA RECEIVING IPILIMUMAB (YERVOY®) AS FIRST-LINE THERAPY

*Sub Investigator*

2009-0288 - Comparative Study of Oncologist Recommended, Home-Based Exercise Program and Relaxation Training for Physical Functioning and Symptom Control in Colon Cancer Patients

*Sub Investigator*

CA209-037 - A Randomized, Open-Label Phase III Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy.

*Sub Investigator*

TPU-TAS-102-301 - RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC COLORECTAL CANCER REFRACTORY TO STANDARD CHEMOTHERAPIES

*Principal Investigator*

Cooperative group study - SWOG Study Phase III Prospective RCT comparison of Octreotide plus Interferon alpha vs Octreotide plus Bevacizumab in advanced poor prognosis carcinoid patients. 5/2012

*Principal Investigator*

ET743-SAR-3007 - "A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma". Janssen Research and Development LLC

*Sub Investigator – Bone Marrow Harvest*

AMORCYTE PreSERVE A Prospective Randomized Double Blinded Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients with Acute Myocardial Infarction.

*Sub Investigator*

CA184-240 - A Single Arm Open-Label Phase II Study of Vemurafenib Followed by a Continuous Administration of Ipilimumab in Subjects with Previously Untreated V600 BRAF Mutated Advanced Melanoma

*Sub Investigator*

103A-301- A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (MAVIS= Melanoma Antigen Vaccine Immunotherapy Study).

*Sub Investigator*

ECOG E1609- A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon  $\alpha$ -2b for Resected High-Risk Melanoma. Eastern Cooperative Oncology Group

*Sub Investigator*

SWOG S1005- A Phase II Study of MK-2206 (NSC-749607) as a Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer. SWOG

*Sub Investigator*

NCCTG N0949- Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer. North Central Cancer Treatment Group

*Sub Investigator*

RTOG 0848 - A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma. RTOG

*Sub Investigator*

C80702 - A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer. Southwest Oncology Group

*Sub Investigator*

IMCL CP15-0806: A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFR $\alpha$  Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue. ImClone Systems Inc.

*Sub Investigator*

BIOVEX 005A- Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEXGM-CSF Compared to Subcutaneously Administered GM-CSF in Previously Treated Melanoma Patients with Unresectable Stage IIIb, IIIc and IV Disease. BIOVEX

**Presentations**

Core Lecture Speaker – Malignant Melanoma 2011- Present

Core Lecture Speaker – Neuroendocrine Malignancies 2012 – Present

Core Lecture Speaker – Bone sarcomas 2014 – Present

Core Lecture Speaker – Soft Tissue sarcomas 2014 - Present

NCAN Speaker "Medical Management of NET disease" 3/2015

CNET Speaker "NET associated Diarrhea" 8/2014

CNET Speaker "Medical Management of Pancreas and Bowel NET" 8/2013

Health Central "Skin Malignancies" 12/2013

Grand Rounds at MDACCO "Current Management of Neuroendocrine Tumors" 11/2012

Journal Club Anti PDI and Anti PDI ligand Phase I studies from NEJM 6/2012 MDACCO

Grand Rounds at MDACCO "Current Update in the Management of Melanoma" 9/2011

Metastatic Breast Cancer 4/2011

Journal Club "JCO 2010 Paper on MSI in Colon Cancer and Adjuvant Therapy" 5/2011

Testicular Malignancies

Sarcoma

CNS Malignancies  
Bladder Cancer  
Metastatic Colorectal Cancer  
CRC Peritoneal Carcinomatosis  
NSCLC  
Journal Club: Brite Registry Data With Use of Bev Beyond 1<sup>st</sup> Progression  
Journal Club: HRPC Phase II with Samarium and Chemotherapy  
Medical Residents/Students/PA Lectures  
Lymphomas, Acute Leukemias, Chronic Leukemias, Plasma cell Dyscrasias, BM  
Failure Syndromes, Myeloproliferative Disorders, Lung Cancer, Anemia, NF, BMT,  
Leukocytosis, Peripheral Smears, Colon, Lung, GI, GU, Melanoma/Sarcoma,  
Head/Neck  
Board Review:  
ASCO-SEP, ASH-SAP, JCO Clinical Diagnosis, MD Anderson BR, HematoPath Lab,  
NCCN CME, ASCO VM, Jeopardy

### **References**

Dan Buchholz– CEO UFHCC Orlando Health 407-247-6192  
Omar Kayaleh – GI Med Onc Section Chief 407-716-2275  
Debu Bose – Chief of GI Surgical Oncology, Leader of Pancreas Center 407-462-5374  
Patrick Kelly – Radiation Oncology for GI Section 407-766-6307  
Carmen Allegra Chief of the Hematology Oncology Division - 352-219-1989

### **Conferences**

Melanoma Symposium New York 2015  
ASCO Chicago 2010, 2011, 2012, 2015  
Neuroendocrine Tumors Ottawa 2012  
Sarcoma and GIST Milan 2012  
GI ASCO Symposium San Francisco 2012, 2013, 2014  
Melanoma Symposium Tampa 2011  
NANET Conference San Diego 2012, Charleston 2013, Tennessee 2014  
NCCN Hollywood 2013

### **Hobbies & Interests**

Piano, basketball, ultimate frisbee, finance, real estate

### **Board Review**

#### **2011-2012 MDAnderson HemOnc Fellow Board Review**

Aug Breast  
Sept Lung, HNC  
Oct Melanoma/Sarcoma, CDO  
Nov GU I/II  
Dec GI I/II  
Jan BioStatistics  
Feb CNS, CDO  
March Gyn I/II  
April Pharmacology I/II  
May Molecular Biology, CDO  
June Epidemiology/Supportive Care, BMT

#### **2010-2011 University of Florida Fellow Board Review**

Breast Cancer Cases with Dr Heldermon (Onc)  
BMT Jeopardy  
Clinical Diagnosis in Oncology (JCO)  
HematoPath Lab Acute Leukemias  
Hematology Meds Part II with Dr Zumberg (Hem)

IMER Mantle Cell Lymphoma  
Hemolytic Anemia with Dr Zumberg (Hem)  
Transfusion Jeopardy  
IMER Ovarian Cancer  
Molecular Biology/Genetics Jeopardy  
HematoPath Lab Low Grade Lymphomas  
Normal B Cell Development with Dr Winters (Immuno)  
IMER Prostate Cancer with Dr Blake  
"Skin Manifestations with Internal Malignancies" with Dr Mitchell (Derm)  
Anemia Jeopardy (Dec 2010)  
IMER MM and SCT (Jan 2011)  
Jay Lynch's Re-hASH (Lymphoma) (Jan 2011)  
Bleeding Disorder Jeopardy (Jan 2011)  
HematoPath Lab Aggressive Lymphomas (Jan 2011)  
Clinical Diagnosis in Oncology (Feb 2011)  
"I have AIDS and I'm Pregnant" Jeopardy (Feb 2011)  
IMER CLL (Feb 2011)  
Gyn Malignancies/Testicular Jeopardy (March 2011)  
IMER CML (March 2011)  
Breast Ca Jeopardy (April 2011)  
"Rare/Uncommon Malignancies" Jeopardy (May 2011)

### **2009-2010 University of Florida Fellow Board Review**

2009

Peripheral Smears: Red Cells/Thrombocytopenia Part I  
Peripheral Smears: Red Cells/Thrombocytopenia Part II  
Peripheral Smears: Malignant Hematology with Graham  
ASCO/NCCN Cetuximab Reaction Iman/Sajeve  
Hemophilia/Hematology Part II Dr Zumberg  
ASH - MDS with Cogle  
Oncotype Dx with Karen Daily  
ASH - Lymphoproliferative disorders, MJ/Lynch/Dang  
Carcinogenesis/Molecular Biology Part I- Bennett  
Carcinogenesis/Molecular Biology Part II- Bennett  
IMER DLBCL Dr Flynn  
ASH - Hemolytic Anemia/Dr Zumberg  
Dang - Informal talk on Mantle Cell and T cell Lymphoma  
Common Skin Infections in Immunocompromized Patients with Dermatology Dr Mitchell  
Thalassemia/Sickle cel q's with Dr Lottenberg  
IMER MDS  
IMER: Multiple Myeloma  
ASH-SAP Transfusion Medicine  
Carcinogenesis/Molecular Biology Part III - Bennett Part III  
ASH-SAP Plasma cell dyscrasia with Dr Moreb  
MD Anderson Review Benign Hematology  
Hematopath Lab Acute Leukemia  
ASH-SAP Myeloid Disorders with Fletcher  
MD Anderson Review Malignant Hematology  
ASH-SAP Hemostasis/Thrombosis

2010

ASH-SAP Iron Metabolism, Acquired Anemia  
IMER: Breast Cancer  
IMER: Melanoma  
Hematopath Lab Benign LAD, Low Grade Lymphoma  
Hematopath Lab Aggressive Lymphomas  
IMER: Renal Cell Carcinoma  
Dr Lynch "Best of ASH Lymphoma"  
IMER CML  
ASCO SEP Breast Cancer QA  
Hematopath MDS subtypes/Myeloproliferative

BAC Julia  
ASCO SEP Sarcoma/Melanoma  
HematoPath Lab Plasma cells/Masto/Eosino/etc Graham  
ASCO SEP GynOnc with MJ  
Dr Grosbach's "Potpourri of Blood Smears"  
GU ASCO-SEP Jeopardy  
Diagnosis in Oncology JCO  
Dr Gopalan's "Carcinoma of Unknown Primary"  
Dr Siddiqui's "Rare Tumors"  
Dr Kim Liver Transplant Hepatobiliary Malignancies  
Dr Pennypacker End of Life Care  
Head/Neck ASCO-SEP Jeopardy